MARYLAND / RankWire.AI / – The U.S. Food and Drug Administration has authorized Rasonque, also known as daraxonrasib, for use in certain adults with metastatic pancreatic adenocarcinoma. Announced on August 26, 2026, this approval pertains to patients who have undergone at least one systemic therapy and those unable to receive multiagent systemic treatments. Revolution Medicines developed this oral medication that specifically targets the RAS GTPase family. Patients are advised to take the drug at a dose of 300 milligrams once daily.
This decision was based on the results of the Phase 3 RASolute 302 study, which involved 500 adults diagnosed with metastatic pancreatic adenocarcinoma. Their cancer had advanced after one previous systemic therapy. Researchers randomized 248 patients to receive daraxonrasib and 252 to physician-selected chemotherapy. The median overall survival was 13.2 months with daraxonrasib, compared to 6.7 months for those on chemotherapy. The trial reported a hazard ratio for death of 0.40, indicating a significant difference between the two groups.
In addition, daraxonrasib demonstrated improvements in key clinical outcomes. The median progression-free survival was 7.2 months in the daraxonrasib cohort, versus 3.6 months among chemotherapy patients. The objective response rate stood at 30% for daraxonrasib and 11% for chemotherapy. Statistically significant differences were observed in overall survival, progression-free survival, and response rate. These findings formed the core clinical evidence underpinning the U.S. approval for previously treated metastatic pancreatic adenocarcinoma.
Clinical trial findings support targeted therapy approval
Daraxonrasib acts by inhibiting active forms of RAS proteins that can promote cancer progression. RAS mutations are present in over 90% of pancreatic ductal adenocarcinomas. The prescribing information does not restrict the indication to patients with a specific RAS mutation. The treatment continues until disease progression or intolerable side effects occur. Revolution Medicines created Rasonque as an oral option for this specific patient population, providing a targeted treatment alternative following initial systemic therapy.
The Phase 3 trial also evaluated safety profiles related to the treatment. Grade 3 or higher adverse events occurred in 61.8% of patients taking daraxonrasib, compared to 69.6% in the chemotherapy group. Treatment-related adverse events led 1.2% of patients on daraxonrasib to discontinue therapy, whereas 11.2% of chemotherapy patients stopped treatment due to side effects. Common adverse reactions include rash, diarrhea, nausea, fatigue, vomiting, abdominal pain, reduced appetite, edema, mouth inflammation, and bleeding.
International regulatory cooperation influenced FDA review process
The prescribing information for Rasonque contains warnings for several serious risks, such as skin and soft tissue toxicity, oral disorders, severe diarrhea, and gastrointestinal perforation. Additional warnings include interstitial lung disease or pneumonitis and embryo-fetal toxicity. The FDA employed expedited review programs, including Real-Time Oncology Review and the Commissioner’s National Priority Voucher pilot, during the evaluation. The agency indicated that it completed the approval roughly 6.5 months before the scheduled regulatory target date.
Furthermore, the FDA collaborated with international regulators through Project Orbis, which promotes coordinated review efforts among global cancer agencies. Health Canada participated in this process. European and Japanese authorities observed the review as official partners. In addition, daraxonrasib received Breakthrough Therapy and Orphan Drug designations in the United States. This approval grants eligible U.S. patients access to Rasonque after previous systemic therapy or when multiagent therapy is unsuitable. The Phase 3 trial’s median overall survival of 13.2 months notably exceeds the 6.7 months observed with chemotherapy.
}**Odh6krqyks**}